It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year) and reducing the risk of fragility fractures. When studied,<unk>  only showed bone mineral density (BMD) improvement during the first 18 months of use.<unk>  should only be used for a period of 2 years maximum. After 2 years, another agent such a bisphosphonate or denosumab should be used in cases of osteoporosis although repeat administration has been used in hypophosphatasia, where bisphosphonates are contraindicated.<unk>  cuts the risk of hip fracture by more than half but does not reduce the risk of arm or wrist fracture. Other<unk>  can be used off-label to speed fracture repair and treat fracture nonunions. It has been reported to have been successfully used to heal fracture nonunions. Generally, due to HIPAA regulations, it is not publicized when American athletes receive this treatment to improve fracture recovery. But an Italian football player, Francesco Totti, was given<unk>  after a tibia/fibula fracture, and he unexpectedly recovered in time for the 2006 World Cup. It has been reportedly used by Mark Mulder of the Oakland A's to recover from a hip fracture before the 2003 MLB playoffs and Terrell Owens to recover from an ankle fracture before the 2005 Super Bowl.<unk>  is currently being trialled with Zoledronic acid as a treatment for Osteogenesis Imperfecta to reduce the risk of broken bones. The trial is due to end in 2023.
Teriparatide
Denosumab
Bolazine capronate
Zoledronic acid
Medronic acid
Alendronic acid
Risedronic acid
Ibandronic acid